USD
+$0.00
(+0.00%
)At Close (As of Nov 5, 2025)
$33.29M
Market Cap
-
P/E Ratio
-0.63
EPS
$2.20
52 Week High
$0.94
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | - |
| Total Revenue | $0 |
| Cost Of Revenue | - |
| Costof Goods And Services Sold | - |
| Operating Income | -$9.6T |
| Selling General And Administrative | $4T |
| Research And Development | $5.5T |
| Operating Expenses | $9.6T |
| Investment Income Net | - |
| Net Interest Income | $125K |
| Interest Income | $125K |
| Interest Expense | $149M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | - |
| Income Before Tax | -$9.5T |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$9.5M |
| Comprehensive Income Net Of Tax | - |
| Ebit | - |
| Ebitda | -$9.6T |
| Net Income | -$9.5T |
| Field | Value (USD) |
|---|---|
| Total Assets | $8.8T |
| Total Current Assets | $1.7T |
| Cash And Cash Equivalents At Carrying Value | $1.6T |
| Cash And Short Term Investments | $1.6T |
| Inventory | - |
| Current Net Receivables | - |
| Total Non Current Assets | $7.2T |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $317B |
| Intangible Assets Excluding Goodwill | $317B |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $112B |
| Other Non Current Assets | - |
| Total Liabilities | $1.3T |
| Total Current Liabilities | $1.3T |
| Current Accounts Payable | $459B |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | - |
| Total Non Current Liabilities | $0 |
| Capital Lease Obligations | - |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | - |
| Other Current Liabilities | $847B |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $7.5T |
| Treasury Stock | - |
| Retained Earnings | -$149T |
| Common Stock | $166M |
| Common Stock Shares Outstanding | $15M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$8.5T |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $736B |
| Capital Expenditures | $57B |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | -$57B |
| Cashflow From Financing | $5.3T |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$9.5T |
| Field | Value (USD) |
|---|---|
| Gross Profit | - |
| Total Revenue | $0 |
| Cost Of Revenue | - |
| Costof Goods And Services Sold | - |
| Operating Income | -$9.6T |
| Selling General And Administrative | $4T |
| Research And Development | $5.5T |
| Operating Expenses | $9.6T |
| Investment Income Net | - |
| Net Interest Income | $125K |
| Interest Income | $125K |
| Interest Expense | $149M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | - |
| Income Before Tax | -$9.5T |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$9.5M |
| Comprehensive Income Net Of Tax | - |
| Ebit | - |
| Ebitda | -$9.6T |
| Net Income | -$9.5T |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
NanoViricides Inc. (NNVC) is an innovative nanobiopharmaceutical firm headquartered in Shelton, Connecticut, dedicated to the research and development of cutting-edge antiviral therapies. Leveraging its proprietary nanomedicine platform, the company creates targeted treatments that address various viral infections and significant unmet medical needs within the healthcare sector. With a robust clinical and preclinical pipeline, NanoViricides is well-positioned for substantial growth in the evolving landscape of antiviral solutions and continues to make strides in bringing its advanced therapies to market.